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ENGINEERING, EXPRESSION SCREENING, AND PRODUCTION CELL LINE DEVELOPMENT OF HETERO
IG MOLECULES USING CHARGE PAIR MUTATIONS
Jennitte Stevens1, Guna Kannan1, Trent Munro2
1Biologics

Optimization and 2Process Development, Amgen, Thousand Oaks

In recent years, there has been an increase in therapeutic indications that require bispecific targeting. Bispecific
Hetero Ig antibodies that can target two antigens have long been considered as an attractive approach to drive
synergistic biologic activity while maintaining the structure and stability of a traditional antibody. However, clinical
development of such molecules has been hampered by CMC related challenges relating to product heterogeneity.
During the development of a Hetero Ig molecule targeting the Wnt pathway antagonists Dkk-1 and SCL-1, we
employed a novel strategy to drive the heterodimerization of IgG antibodies through the addition of charge pair
reside mutations (CPM) at both the heavy chain and light chain surface interface. Through electrostatic
interactions, these CPMs drive appropriate chain pairing, while minimizing undesired side products. During
engineering and expression in transient expression systems, we identified combinations of single residue pair
mutations that promoted correct chain pairing. However, the combination of antibody pairs and expression balance
is important to enable reduction in undesired side products. These findings extend to stable cell line development,
where vector design and appropriate analytics enable the identification of pools and then clones with desired
product quality. We have expanded this strategy for the development of a platform approach toward the efficient
development of HeteroIg molecules.

